Pliant Therapeutics (PLRX) Change in Accured Expenses (2019 - 2026)
Pliant Therapeutics (PLRX) reported Change in Accured Expenses of -$6.5 million for Q1 2026, down 34.65% year-over-year from -$9.9 million in Q1 2025, and down 327.61% quarter-over-quarter from -$1.5 million in Q4 2025.
Pliant Therapeutics (PLRX) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Change in Accured Expenses data on file, last reported at -$6.5 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$6.5 million, down 34.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$13.8 million (down 15101.1% YoY), and the FY2025 annual result was -$12.2 million, down 419.6% from the prior year.
- Change in Accured Expenses fell to -$6.5 million in Q1 2026 per PLRX's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $5.8 million in Q2 2022 and troughed at -$6.5 million in Q1 2026.
- A 5-year average of -$244058.8 and a median of -$538000.0 in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 659.95% in 2022, then plunged 976.68% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at -$411000.0 in 2022, then soared by 270.07% to $699000.0 in 2023, then sank by 976.68% to -$6.1 million in 2024, then surged by 75.29% to -$1.5 million in 2025, then plunged by 327.61% to -$6.5 million in 2026.
- Business Quant data shows PLRX's Change in Accured Expenses at -$6.5 million in Q1 2026, -$1.5 million in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - | -6.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.47 Mn |
| Mar 31, 2026 | -6.47 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | -2.03 Mn |
| Sep 30, 2025 | -2.03 Mn |
| Jun 30, 2025 | -3.81 Mn |
| Jun 30, 2025 | -3.81 Mn |
| Mar 31, 2025 | -4.81 Mn |
| Mar 31, 2025 | -4.81 Mn |
| Dec 31, 2024 | -6.13 Mn |
| Dec 31, 2024 | -6.13 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 5.68 Mn |
| Jun 30, 2024 | 5.68 Mn |
| Mar 31, 2024 | -910,000.00 |
| Mar 31, 2024 | -910,000.00 |
| Dec 31, 2023 | 699,000.00 |
| Dec 31, 2023 | 699,000.00 |